Skip to main content

Cody Keetch

(he/him/his)

Associate

[email protected]

+1.212.692.6760

Share:

Cody focuses his practice on health care transactions and advises health care organizations on regulatory, compliance, and governance matters. He regularly negotiates and drafts documents for mergers, acquisitions, and reorganizations. Cody assists clients with formation and dissolution, governance disclosures to state regulatory bodies, employment agreements, and licensure and certification applications. His practice involves preparing a wide variety of corporate and commercial agreements, including license and service agreements. In addition, Cody represents clients in the technology and life sciences industries.

Prior to joining Mintz, Cody was an associate at a Long Island, New York–based boutique law firm that serves the health care industry, where he handled transactional, corporate, and compliance matters.

While attending law school, Cody had a number of internships and externships focusing on legal issues affecting the health care sector, including with the Health Care Bureau of the New York State Attorney General’s Office and the Centers for Disease Control and Prevention in Atlanta,  researching and drafting pleadings, motions, and memorandums on health law and other legal issues. Cody also worked as a legal extern at the American Cancer Society in Atlanta and a legal intern at the Children's Cancer & Blood Foundation in New York, where he focused on contracting and corporate governance matters.

Cody participated in the Transactional Law Certificate Program at Emory University School of Law.

Education

  • Emory University (JD)
  • University of Michigan (BA)

Languages

- Spanish

Viewpoints

Health Care Viewpoints Thumbnail
On Friday, August 6, 2021, Pharmaceutical Research and Manufacturers of America (PhRMA), the preeminent trade association representing pharmacies companies, announced revisions to its Code on Interactions with Health Care Professionals (PhRMA Code) that will become effective January 1, 2022. The PhRMA Code is a voluntary code for pharmaceutical companies, but its standards are considered to be best practices and are commonly adhered to by pharmaceutical and medical device companies. Moreover, some states (e.g. California, Massachusetts, Nevada, and the District of Columbia) require pharmaceutical companies to adopt a code consistent with the PhRMA Code.

The changes to the PhRMA Code are undoubtedly in response to a November 16, 2020, Special Fraud Alert from the Department of Health and Human Services’ Office of the Inspector General (OIG), on “fraud and abuse risks associated … speaker programs.” (For additional information on the OIG’s Special Fraud Alert, please see our November 25, 2020 blog post.) Speaker programs are a common practice in the industry and generally entail pharmaceutical and medical device companies retaining health care professionals (HCPs) to speak or present to educate their peers on the companies’ drugs or devices.
Read more
Health Care Viewpoints Thumbnail
On June 24, 2021, the Food and Drug Administration (FDA) issued the long-awaited Remanufacturing of Medical Devices Draft Guidance, which describes the agency’s current thinking on activities that meet the definition of remanufacturing and a process for determining whether an act done to an original equipment manufacturer’s (OEM’s) legally marketed finished device is considered remanufacturing (the “Draft Remanufacturing Guidance”).
Read more
Health Care Viewpoints Thumbnail

The American Families Plan & A Call for Drug Pricing Legislation

May 10, 2021 | Blog | By Theresa Carnegie, Cody Keetch

On April 28, 2021, President Biden gave his first address to Congress and announced the American Families Plan (AFP). The AFP follows the 1.9 trillion-dollar stimulus, the American Rescue Plan Act, signed into law on March 11, 2021. Notably, in his speech, President Biden called upon Congress to pass drug pricing legislation; however, the current White House Fact Sheet on the AFP does not include specific drug pricing provisions. This blog post discusses the health-related portions of the AFP and provides an overview of the Lower Drug Costs Now Act which seeks to lower prescription drug prices.
Read more